Daiichi Sankyo and Merck Announce FDA Acceptance of BLA for Patritumab Deruxtecan with Priority Review for EGFR-Mutated NSCLC

Daiichi Sankyo Company Limited and MSD announced on December 22 that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for patritumab deruxtecan and granted it Priority Review. This drug is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease has progressed during or after treatment with a third-generation tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.